TY - JOUR AU - Musolino, Antonino AU - Campone, Mario AU - Neven, Patrick AU - Denduluri, Neelima AU - Barrios, Carlos H. AU - Cortes, Javier AU - Blackwell, Kimberly AU - Soliman, Hatem AU - Kahan, Zsuzsanna AU - Bonnefoi, Hervé AU - Squires, Matthew AU - Zhang, Yong AU - Deudon, Stephanie AU - Shi, Michael M. AU - André, Fabrice PY - 2017 DA - 2017/02/10 TI - Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy JO - Breast Cancer Research SP - 18 VL - 19 IS - 1 AB - Overexpression of fibroblast growth factor receptor 1 (FGFR1), found in ≤8% of hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) breast cancer cases, is correlated with decreased overall survival and resistance to endocrine therapy (ET). Dovitinib, a potent FGFR inhibitor, has demonstrated antitumor activity in heavily pretreated patients with FGFR pathway–amplified breast cancer. SN - 1465-542X UR - https://doi.org/10.1186/s13058-017-0807-8 DO - 10.1186/s13058-017-0807-8 ID - Musolino2017 ER -